SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Business
During COVID-19, Biotech Professionals Feel Isolated and Less Productive
A vaccine for COVID-19 is unlikely to be ready in 2020, according to biopharma professionals responding to the BioSpace Workplace Survey: The Impact of COVID-19 – Spring 2020. Only 25% of respondents thought a vaccine might be possible this year.
April 30, 2020
 · 
1 min read
 · 
Gail Dutton
Business
Faster Drug Development Processes Likely to Outlive COVID-19
The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients.
April 30, 2020
 · 
5 min read
 · 
Gail Dutton
AbCellera and Lilly Slash Antibody Selection Time for COVID-19 With AI/Machine Learning
With the trillions of antibodies the human body can make, finding the antibody with the right combination of potency against a target and ease of manufacturing is, at best, an arduous, time-intensive endeavor for drug developers. AbCellera Biologics has developed a way to dramatically speed that process.
April 28, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Mammoth’s CRISPR Assay for Asymptomatic COVID-19 Carriers Gains Peer-Reviewed Validation
Following news of Mammoth Biosciences’ CRISPR diagnostic assay to detect SARS-CoV-2, the company talked at length with BioSpace about this new test and its ramifications.
April 24, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Pluristem Advances Placental Cells to Modulate COVID-19 Cytokine Storm
Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.
April 23, 2020
 · 
4 min read
 · 
Gail Dutton
Psychedelics Make a Comeback as Therapies for Brain Injury, PTSD, Anxiety and Even Addiction
The interest in psychedelic medicine – particularly psilocybin, a pro-drug derived from some 200 varieties of the so-called magic mushrooms – stems from multiple factors.
April 22, 2020
 · 
4 min read
 · 
Gail Dutton
Business
FDA and Immunology Experts Call for Flexible Trial Design for Pandemic Vaccines
Traditional vaccine development and regulatory policies are changing in response to the current pandemic. Some of those approaches may become more common, expanding into other, non-pandemic-related areas in the future.
April 20, 2020
 · 
5 min read
 · 
Gail Dutton
iQ Capital Says Seed Financing Remains Available Despite Volatile Economic Conditions
Despite the poor Q1 economic data that is beginning to be released, the equity markets are stabilizing.
April 17, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Ligandal Proposes ‘Antidote’ to COVID-19 Using Robot-like Peptide Scaffolds
The company suggests its approach can actually help eliminate the virus from an already-infected host, while also bolstering the immune response.
April 16, 2020
 · 
3 min read
 · 
Gail Dutton
Biotech Beach
Beyond COVID-19: Biotech Beach Companies Reinvigorate Small Molecules, Cannabinoids and More
The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.
April 15, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Origin Ramps Up Production of 3D-Printed Test Swabs
Origin, a 3D printing specialist for medical devices, just completed clinical trials and validation of its 3D-printed nasopharyngeal swabs for use in COVID-19 test kits. It is scaling up production and accepting orders to manufacture millions of the swabs.
April 14, 2020
 · 
5 min read
 · 
Gail Dutton
Business
The 1968 Pandemic Strain (H3N2) Persists. Will COVID-19?
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
April 13, 2020
 · 
4 min read
 · 
Gail Dutton
Business
AMA Doubles Down Against Off-Label Prescriptions, Despite Promising Evidence
On Thursday, the American Medical Association doubled down on its stance against using off-label medicines like hydroxychloroquine and chloroquine to treat COVID-19 patients.
April 10, 2020
 · 
5 min read
 · 
Gail Dutton
Business
Biotech Beach Emergent BioSolutions Aims to Fight COVID-19
Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight.
April 9, 2020
 · 
2 min read
 · 
Gail Dutton
Drug Development
Revolutionizing the Manufacturing Process for Faster Vaccine and Therapeutic Production
The fastest way to get a safe, effective vaccine for COVID-19 to physicians and patients is to build upon an existing vaccine with an already-established manufacturing and supply chain…or to revolutionize the manufacturing process.
April 8, 2020
 · 
4 min read
 · 
Gail Dutton
Load More